Top

Published in:

01-12-2011 | Urinary Tract Infections (Jack D. Sobel, Section Editor)

Urinary Tract Infections in Patients with Spinal Cord Injuries

Authors: Frederiek D’Hondt, Karel Everaert

Published in: Current Infectious Disease Reports | Issue 6/2011

Abstract

Spinal cord injuries (SCI) result in different lower urinary tract dysfunctions. Because of both the disease and the bladder drainage method, urinary tract infections (UTIs) are one of the most frequent conditions seen in SCI patients. Diagnosis is not always easy due to lack of symptoms. Asymptomatic bacteriuria needs no treatment. If symptoms occur, antibiotherapy is indicated. Duration depends mainly on severity of illness and upper urinary tract or prostatic involvement. Choice of antibiotherapy should be based on local resistance profiles, but fluoroquinolones seems to be an adequate empirical treatment. Prevention of UTI is important, as lots of complications can be foreseen. Catheter care, permanent low bladder pressure and clean intermittent catheterization (CIC) with hydrophilic catheters are interventions that can prevent UTI. Probiotics might be useful, but data are limited.

Evans CT, LaVela SL, Weaver FM, et al. Epidemiology of hospital-acquired infections in veterans with spinal cord injury and disorder. Infect Control Hosp Epidemiol. 2008;29:234–42.PubMedCrossRef

García Leoni ME, Esclarín De Ruz A. Management of urinary tract infection in patients with spinal cord injuries. Clin Microbiol Infect. 2003;9:780–5.PubMedCrossRef

van den Berg ME, Castellote JM, de Pedro-Cuesta J, Mahillo-Fernandez I. Survival after spinal cord injury: a systematic review. J Neurotrauma. 2010;27:1517–28.PubMedCrossRef

Sekar P, Wallace DD, Waites KB, et al. Comparison of long-term renal function after spinal cord injury using different urinary management methods. Arch Phys Med Rehabil. 1997;78:992–7.PubMedCrossRef

Waites KB, Canupp KC, DeVivo MJ. Eradication of urinary tract infection following spinal cord injury. Paraplegia. 1993;31:645–52.PubMedCrossRef

Siroky MB. Pathogenesis of bacteriuria and infection in the spinal cord injured patient. Am J Med. 2002;113(Suppl 1A):67S–79S.PubMedCrossRef

•• Singh R, Rohilla RK, Sangwan K, et al. Bladder management methods and urological complications in spinal cord injury patients. Indian J Orthop. 2011;45:141–7. Prospective study over 12 years (545 patients included) to investigate the main complications of different drainage techniques used in SCI-patients.PubMedCrossRef

Jeong SJ, Cho SY, Oh SJ. Spinal cord/brain injury and the neurogenic bladder. Urol Clin North Am. 2010;37:537–46.PubMedCrossRef

Wein AJ, Kavoussi LR, Novick AC, et al. In: Wein AJ, editor. Campbell-Walsh urology ninth edition: lower urinary tract dysfunction in neurologic injury and disease. Philadelphia: Saunders Elsevier; 2007. p. 2011–31.

10.

• Gormley EA. Urologic complications of the neurogenic bladder. Urol Clin North Am. 2010;37:601–7. This article provides an overview of the urologic complications of the adult neurogenic bladder.PubMedCrossRef

11.

National Institute on Disability and Rehabilitation Research (NIDRR) consensus statement, January 27–29, 1992: the prevention and management of urinary tract infections among people with spinal cord injuries. J Am Paraplegia Soc. 1992;15:194–204.

12.

• Massa LM, Hoffman JM, Cardenas DD. Validity, accuracy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization. J Spinal Cord Med. 2009;32:568–73. The UTI signs and symptoms can predict a UTI more accurately than individual subjects can by using subjective impressions of their own signs and symptoms. Subjects were better at predicting when they did not have a UTI than when they did have a UTI.PubMed

13.

Cardenas DD, Hooton TM. Urinary tract infection in persons with spinal cord injury. Arch Phys Med Rehabil. 1995;76:272–80.PubMedCrossRef

14.

Menon EB, Tan ES. Pyuria: index of infection in patients with spinal cord injuries. Br J Urol. 1992;69:144–6.PubMedCrossRef

15.

Hoffman JM, Wadhwani R, Kelly E, et al. Nitrite and leukocyte dipstick testing for urinary tract infection in individuals with spinal cord injury. J Spinal Cord Med. 2004;27:128–32.PubMed

16.

Everaert K, Delanghe J, Vande Wiele C, et al. Urinary alpha 1-microglobulin detects uropathy. A prospective study in 483 urological patients. Clin Chem Lab Med. 1998;36:309–15.PubMedCrossRef

17.

Everaert K, Delanghe J, Vanderkelen M, et al. Urinary plasma protein patterns in acute prostatitis. Clin Chem Lab Med. 2003;41:79–84.PubMedCrossRef

18.

Esclarín De Ruz A, García Leoni E, Herruzo Cabrera R. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol. 2000;164:1285–9.PubMedCrossRef

19.

Montgomerie JZ. Infections in patients with spinal cord injuries. Clin Infect Dis. 1997;25:1285–90.PubMedCrossRef

20.

Sugimura T, Arnold E, English S, et al. Chronic suprapubic catheterization in the management of patients with spinal cord injuries: analysis of upper and lower urinary tract complications. BJU Int. 2008;101:1396–400.PubMedCrossRef

21.

Feifer A, Corcos J. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn. 2008;27:475–9.PubMedCrossRef

22.

Mitsui T, Minami K, Furuno T, et al. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol. 2000;38:434–8.PubMedCrossRef

23.

Weld KJ, Dmochowski RR. Effect of bladder management on urological complications in spinal cord injured patients. J Urol. 2000;163:768–72.PubMedCrossRef

24.

Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord. 2002;40:536–41.PubMedCrossRef

25.

Galloway A. Prevention of urinary tract infection in patients with spinal cord injury—a microbiological review. Spinal Cord. 1997;35:198–204.PubMedCrossRef

26.

Biering-Sørensen F, Bagi P, Høiby N. Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs. 2001;61:1275–87.PubMedCrossRef

27.

Penders J, Huylenbroeck AA, Everaert K, et al. Urinary infections in patients with spinal cord injury. Spinal Cord. 2003;41:549–52.PubMedCrossRef

28.

Tenke P, Kovacs B, Bjerklund Johansen TE, et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents. 2008;31S:S68–78.CrossRef

29.

•• Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:625–63. Guidelines for the diagnosis, prevention, and management of persons with catheter-associated urinary tract infection (CA-UTI), both symptomatic and asymptomatic, were prepared by an Expert Panel of the Infectious Diseases Society of America.PubMedCrossRef

30.

•• Everaert K, Lumen N, Kerckhaert W, et al. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg. 2009;64:335–40. Overview of the literature for treatment and prevention of UTI in SCI patients.PubMed

31.

Reid G, Potter P, Delaney G, et al. Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury. Int J Antimicrob Agents. 2000;13:305–7.PubMedCrossRef

32.

Dow G, Rao P, Harding G, et al. A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury. Clin Infect Dis. 2004;39:658–64.PubMedCrossRef

33.

Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control. 2004;32:177–83.PubMedCrossRef

34.

Salomon J, Denys P, Merle C, et al. Prevention of urinary tract infection in spinal cord-injured patients: safety and efficacy of a weekly oral cyclic antibiotic (WOCA) programme with a 2 year follow-up—an observational prospective study. J Antimicrob Chemother. 2006;57:784–8.PubMedCrossRef

35.

Morton SC, Shekelle PG, Adams JL, et al. Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction. Arch Phys Med Rehabil. 2002;83:129–38.PubMedCrossRef

36.

Bennett CJ, Young MN, Razi SS, et al. The effect of urethral introducer tip catheters on the incidence of urinary tract infection outcomes in spinal cord injured patients. J Urol. 1997;158:519–21.PubMedCrossRef

37.

Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev. 2004;(2):CD004375.

38.

Moore KN, Fader M, Getliffe K. Long-term bladder management by intermittent catheterisation in adults and children. Cochrane Database Syst Rev. 2007;17(4):CD006008.

39.

• Chartier-Kastler E, Denys P. Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retention. Neurourol Urodyn. 2011;30:21–31. This article (and ref 40) support the benefits of hydrophilic catheters in terms of safety and quality of life.PubMedCrossRef

40.

• Cardenas DD, Hoffman JM. Hydrophilic catheters versus noncoated catheters for reducing the incidence of urinary tract infections: a randomized controlled trial. Arch Phys Med Rehabil. 2009;90:1668–71. This article (and ref 39) support the benefits of hydrophilic catheters in terms of safety and quality of life.PubMedCrossRef

41.

De Ridder DJ, Everaert K, Fernández LG, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Eur Urol. 2005;48:991–5.PubMedCrossRef

42.

Vapnek JM, Maynard FM, Kim J. A prospective randomized trial of the LoFric hydrophilic coated catheter versus conventional plastic catheter for clean intermittent catheterization. J Urol. 2003;169:994–8.PubMedCrossRef

43.

van Nieuwkoop C, den Exter PL, Elzevier HW, et al. Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation. Int J Antimicrob Agents. 2010;36:485–90.PubMedCrossRef

44.

Lee BB, Simpson JM, Craig JC, Bhuta T. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2007;17(4):CD003265.

45.

Opperman EA. Cranberry is not effective for the prevention or treatment of urinary tract infections in individuals with spinal cord injury. Spinal Cord. 2010;48:451–6.PubMedCrossRef

46.

Hull R, Rudy D, Donovan W, et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. J Urol. 2000;163:872–7.PubMedCrossRef

47.

Anukam KC, Hayes K, Summers K, et al. Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 may help downregulate TNF-Alpha, IL-6, IL-8, IL-10 and IL-12 (p70) in the neurogenic bladder of spinal cord injured patient with urinary tract infections: a two-case study. Adv Urol. 2009:680363. Epub 2009 Jun 4.

48.

Gamé X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53:613–8.PubMedCrossRef

Title: Urinary Tract Infections in Patients with Spinal Cord Injuries
Authors: Frederiek D’Hondt
Karel Everaert
Publication date: 01-12-2011
Publisher: Current Science Inc.
Published in: Current Infectious Disease Reports / Issue 6/2011
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-011-0208-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients

Recurrent Urinary Tract Infections in Kidney Transplant Recipients

Long-Term Voriconazole and Skin Cancer: Is There Cause for Concern?

Current Role of Echinocandins in the Management of Invasive Aspergillosis

Herpes Simplex Virus Genital Infections: Current Concepts

Update in Adult Urinary Tract Infection

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials